Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a partnership with Nanjing Bioheng Biotech Co., Ltd to develop and domesticate raw materials for cell therapies. The collaboration focuses on the process development and raw materials domestication of universal chimeric antigen receptor (CAR)-T therapies. Bioheng, a developer of universal CAR-T therapies, will utilize Kactus’s GMP-compliant Cas9 raw material enzyme for cell gene editing, aiming to accelerate the commercialization and accessibility of these innovative treatments. Financial details of the partnership were not disclosed.
Company Overview and Collaboration
Founded in 2018, Kactus Biosystems has established itself as a leader in protein research and development, boasting the unique SAMSTM platform. The company offers a range of products, including universal nucleases for the AAV and vaccine industry, cytokines for cell therapy, and raw material enzymes for mRNA vaccine production. Bioheng Biotech, on the other hand, specializes in immune cell therapy and gene therapy, with a focus on developing a fifth-generation universal CAR-T therapy. This advanced therapy aims to make immune cell and gene therapies more affordable and accessible to patients.
Future Outlook
The partnership between Kactus Biosystems and Bioheng Biotech underscores the commitment of both companies to advancing innovative treatments in the field of cell and gene therapy. By leveraging Kactus’s GMP-compliant Cas9 enzyme and Bioheng’s expertise in CAR-T development, the collaboration aims to enhance the commercial viability and reach of universal CAR-T therapies. This strategic move highlights the potential for significant advancements in making cutting-edge treatments more widely available to patients in need.-Fineline Info & Tech
